surufatinib
-
HUTCHMED Advances Surufatinib/Camrelizumab Combo to Phase III for Untreated Pancreatic Cancer
HUTCHMED has advanced its pancreatic cancer program to Phase III, initiating a trial for a combination therapy of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine (S+C+AG) for metastatic PDAC in China. Promising Phase II results showed significant improvements in progression-free survival and objective response rate compared to the standard chemotherapy regimen. The Phase III trial will evaluate overall survival as the primary endpoint in approximately 400 additional patients.
-
HUTCHMED to Present Clinical Data at the 2025 ESMO Asia Congress and ASH Annual Meeting
HUTCHMED will unveil new clinical data at ESMO Asia (Dec 5‑7, 2025, Singapore) and ASH (Dec 6‑9, 2025, Orlando). Highlights include first‑in‑human results for the anti‑CD47 antibody HMPL‑A83, Phase II FRUSICA‑2 readouts of fruquintinib + sintilimab in second‑line renal cell carcinoma, Phase II data on surufatinib + camrelizumab + chemotherapy for metastatic pancreatic cancer, and the final Phase III analysis of sovleplenib (ESLIM‑01) in chronic primary immune thrombocytopenia. These disclosures mark key milestones for the company’s oncology and immune‑mediated pipelines.
